medRxiv preprint doi: https://doi.org/10.1101/2024.12.20.24319407; this version posted December 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

Systematic review and individual patient data meta-1 analysis on glucose- 6 – phosphate dehydrogenase 2 activities measured by a semi-quantitative handheld 3 **Biosensor** 4

6 Benedikt Ley ^{1,2}*, Laura Rojas Vasquez³, Avyinaeesh Sitsabasan³, Bipin Adhikari^{4,5}, Nabaraj Adhikari⁶, 7 Mohammad Shafiul Alam⁷, Santasabuj Das⁸, Prakash Ghimire⁶, Marcus V. G. Lacerda^{9,10,11}, Ric N. 8 Price^{1,4,5}, Komal Raj Rijal⁶, Lorenz von Seidlein^{4,5}, Arunansu Talukdar¹², Kamala Thriemer¹, Ari Winasti 9 Satyagraha^{13,14}, Arkasha Sadhewa¹, Megha Rajasekhar¹⁵, Robert J. Commons ^{1,3} 10 1. Global Health Division, Menzies School of Health Research and Charles Darwin University, 11 12 Darwin, Australia 13 2. Division of Teaching, Menzies School of Health Research and Charles Darwin University, 14

- Darwin, Australia
 - 3. General and Subspecialty Medicine, Grampians Health Ballarat, Ballarat, Victoria, Australia
- 4. Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
- 18 5. Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, 19 University of Oxford, Oxford, UK 20
 - 6. Central Department of Microbiology, Tribhuvan University, Kathmandu, Nepal
 - 7. International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
 - 8. National Institute of Cholera and Enteric Diseases, Kolkata, India
- 23 9. Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil
- 24 10. Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Brazil
- 25 11. University of Texas Medical Branch, Galveston, TX, USA
- 26 12. Kolkata Medical College Hospital, India
- 27 13. Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, 28 Cibinong, Indonesia 29
 - 14. EXEINS Health Initiative, Jakarta, Indonesia
- 30 15. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global 31 Health, The University of Melbourne, Melbourne, VIC, Australia

32 33

5

15

16

17

21

22

- 34 *Corresponding author: benedikt.ley@menzies.edu.au
- 35
- 36
- 37

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

38 Abstract

39 Measurement of glucose-6-phosphate dehydrogenase (G6PD) activity guides hypnozoitocidal 40 treatment of P. vivax malaria. The G6PD Standard (SDBiosensor, Republic of Korea) here referred to as 41 "Biosensor" is a quantitative point-of-care diagnostic that measures G6PD activity in U/gHb . The 42 manufacturer recommends cutoffs to define G6PD deficient (<4.0U/gHb), intermediate (4.1-43 ≤6.0U/gHb) and normal (>6.0U/gHb) individuals. The aim of this individual patient data (IPD) meta-44 analysis was to evaluate these cutoffs (CRD42023406595).

- 45 A systematic review identified studies reporting population-level G6PD activity measured by Biosensor, 46 published between January 2017 and May 2023. IPD were collated and standardised. The adjusted 47 male median (AMM) was defined as 100% activity and calculated across all studies (universal AMM) 48 and separately for each setting. The proportion of participants classified as deficient or intermediate 49 were compared using the manufacturer-recommended cutoffs and 30% and 70% of the universal 50 AMM and setting-specific AMM. Associations between G6PD activity and blood sampling method, 51 malaria status, and age were assessed.
- 52 Eleven studies with 9,724 participants from eight countries were included in this analysis. The universal 53 AMM was 7.7U/gHb and the setting-specific AMMs ranged from 6.2U/gHb to 9.9U/gHb. When using 54 the universal AMM, 4.2% of participants were classified as deficient and 11.9% as intermediate or 55 deficient. The corresponding values were 3.9% and 10.8% for setting-specific cutoffs, and 7.2% and 56 18.3% for manufacturer-recommended definitions for deficients and intermediates respectively. The 57 manufacturer-recommended cutoff for deficient individuals fitted the distribution of G6PD activities 58 better than definitions based on the percentage of AMM. There was no significant association between 59 malaria status or blood sampling method and G6PD activity. Measured G6PD activity decreased in 60 children 1 to 5 years and plateaued thereafter. 61 The manufacturer's recommended cutoff is conservative but more reliable at categorising G6PD
- 62 deficient individuals than those based on calculations of 30% activity using the AMM. The observed
- 63 decrease in G6PD activity in children between 1 to 5 years of age warrants further investigation.
- 64
- 65

66 Background

67 Nearly 3.3 billion people are at risk of a *Plasmodium vivax* (*P. vivax*) infection [1-3]. In contrast to other 68 malaria species *P. vivax* forms dormant liver stage hypnozoites that relapse weeks to months after a 69 primary infection causing significant morbidity and mortality [4]. These hypnozoites represent a silent 70 reservoir that complicates the elimination of *P. vivax* [5]. The 8-aminoquinolines, primaguine and 71 tafenoquine, are the only licensed drugs that kill hypnozoites; although both drugs can cause severe 72 haemolysis in patients with low glucose-6-phosphate dehydrogenase enzyme (G6PD) activity [6, 7]. 73 G6PD is found in all eukaryotic cells and is essential in human red blood cells (RBCs) to maintain their

- 74 redox potential [8, 9]. Enzyme activity is measured in international units (U), normalised by a 75 haemoglobin (Hb) measurement (U/gHb) taken at the same time [10]. Since the phenotypic reference 76 method, spectrophotometry, is poorly standardised, the output in U/gHb is converted to percent
- 77 activity (%) based on the adjusted male median (AMM), to enable comparison across populations [11].
- 78 To calculate the AMM, the median activity of all male individuals from the same population is
- 79 calculated, all observations with values less than 10% of this median are then excluded and the median
- 80 activity is recalculated from the remaining subset and defined as 100% activity [12]. More than 230
- 81 clinically relevant genetic G6PD variants have been described to date, associated with reduced G6PD
- 82 activities, collectively called G6PD deficiency [8, 13, 14].

83 The G6PD gene is located on the X-chromosome. Males have one copy of the gene and are hemizygous 84 deficient or normal. Females have two copies and can be either homozygous deficient, homozygous 85 normal, or heterozygous for the gene. Most hemizygous and homozygous deficient individuals have 86 phenotypic G6PD activities below 30% and G6PD normal individuals have activities above 70% to 80% 87 [15]. In comparison, heterozygous females have a wide range of G6PD activities from deficient to 88 normal [8]. Accordingly, G6PD activities within a population show a bimodal distribution, with 89 activities of the majority of individuals normally distributed around the 100% activity mark and a 90 second smaller peak representing hemizygous and homozygous deficient individuals (Fig 1) [16].

91

92 Fig 1: G6PD activities in samples collected from participants in Bangladesh during a cross-sectional

93 survey measured by spectrophotometry





94

95 Vertical lines from left to right indicate 10%, 30% 70% and 100% G6PD activity [16]

96

97 The World Health Organization (WHO) recommends testing patients for G6PD deficiency prior to 98 treatment with daily primaguine regimens to identify patients with reduced activity and tailor their 99 treatment accordingly [17]. Patients with G6PD activity <30% should not receive 7- or 14-day 100 primaguine regimens. Tafenoquine is only recommended for patients with \geq 70% G6PD activity [18, 101 19]. In 2022 the WHO revised their classification of G6PD variants, recommending that any variant 102 with a median activity <45% (Class B) by spectrophotometry should be considered clinically significant 103 [14, 20, 21]. Although spectrophotometry is the reference method to measure G6PD activity, it is 104 unsuitable for point of care testing [22]. To date, the only point of care test that can reliably 105 discriminate activities between 30% and 70% is the handheld semi-quantitative Biosensor from SD 106 Biosensor (STANDARD G6PD, ROK; Biosensor) [22-25]. The Biosensor generates G6PD (in U/gHb) and 107 haemoglobin (in g/dL) readings from 10 μ l of capillary or venous blood within two minutes. The 108 manufacturer recommends thresholds of 4.0 U/gHb and 6.0 U/gHb to discriminate deficient and 109 intermediate activities respectively [26]. Alignment of these cutoffs with local AMM-derived 30% and 110 70% cutoffs have varied considerably [27]. This individual patient data pooled analysis aimed to assess 111 whether the manufacturer-recommended cutoffs for the Biosensor are universally applicable.

112

113 Methods

114 Search strategy and selection criteria

115 A systematic review of Medline, Web of Science, Cochrane Central, Scopus, Clinicaltrials.gov and the 116 WHO International clinical trials registry platform was undertaken to identify studies that measured 117 population-based G6PD activity using the G6PD Standard point of care test (Biosensor) manufactured 118 by SD Biosensor (Republic of Korea) between January 1, 2017, and May 17, 2023, in any language. 119 Search terms used were ((G6PD) OR (G6PD deficiency) OR (Glucose-6-phosphate dehydrogenase) OR 120 (Glucose-6-phosphate dehydrogenase deficiency)) AND ((G6PD Standard) OR (SDBiosensor) OR (SD 121 Biosensor) OR (Standard G6PD) OR tafenoquine). Studies were included if they reported activities of 122 at least 36 randomly selected male individuals older than 1 year from a population expected to have 123 a G6PD distribution consistent with the local population. Four reviewers undertook the systematic 124 review (AS, BL, LRV and RJC) with each article screened by two reviewers and discrepancies resolved 125 by discussion. The protocol was registered with PROSPERO CRD42023406595.

126 Investigators of studies eligible for inclusion were invited to contribute individual patient data in 127 addition to any data from eligible but unpublished studies. Data collected included age, sex, malaria 128 status, G6PD activity (in U/gHb) and haemoglobin (in g/dL) measured by Biosensor, date of G6PD 129 measurement, methodology of blood collection (capillary versus venous), pregnancy status, date of 130 last malaria episode, and history of giving birth, blood loss or major surgery in the previous 6 months. 131 Individual patient data were excluded if missing age, sex, G6PD activity, or haemoglobin, or if 132 haemoglobin was <7 g/dL on the Biosensor measurement, as recommended by the manufacturer.

133 Data were obtained according to ethical approvals from the original study. Our analysis did not require 134 additional ethical approval as the original data approved by ethical review boards were anonymised 135 and unable to be linked to individuals.

136

137 Definitions

138 Each combination of country and study group was defined as a 'setting'. The blood sampling technique 139 was categorised as venous or capillary. The AMM was defined as 100% activity and calculated from 140 male participants above one year of age who tested negative for malaria by microscopy or rapid 141 diagnostic test (RDT) and after removal of participants with the lowest 10% of reported G6PD activities 142 [12]. The AMM was calculated for the entire data set (universal AMM) and separately for each setting 143 (setting-specific AMM). G6PD deficient and intermediate status of all included participants were 144 categorised repeatedly: i) as measured activity of less than 30% and 70% of the universal AMM, ii) as 145 measured activity of less than 30% and 70% of the setting-specific AMM, and iii) when applying the 146 manufacturer recommended cut-off of 4.0 U/gHb and 6.0 U/gHb, respectively.

147

148 Statistical Analysis

149 All observations were categorised three times based on the different definitions of deficient and 150 intermediate activities and proportions of deficient and intermediate individuals were compared. The 151 distribution of G6PD activities was plotted by sex for the overall population and by setting. The 152 association between blood sampling method (capillary or venous) and G6PD activity was assessed in 153 studies that sampled using both capillary and venous methods. The relationship was analysed using 154 multivariable linear regression adjusting for age, sex, baseline Hb, and malaria status with robust 155 errors and clustering by setting. Using a similar multivariable linear regression model restricted to 156 studies which included participants both with or without malaria, the association between malaria 157 presence and G6PD activity was investigated. The relationship between age and G6PD activity was 158 also investigated in a similar model. Due to a non-linear relationship between age and G6PD activity, 159 a post hoc analysis was undertaken with a generalised estimating equations model to visualise the 160 relationship between G6PD activity and age with fractional polynomial terms fitted for age, 161 adjustment for age, sex, baseline Hb, and blood sampling method and clustering by setting. This 162 relationship was explored separately in all participants, in males and females. Separate sensitivity 163 analyses were undertaken restricted to males with i) a haemoglobin >10 g/dL and ii) excluding those 164 with an activity \leq 4.0 U/g Hb (presumed deficient).

165 The within-study risk of bias assessment was performed using the QUADAS-2 tool [28]. Analyses were166 undertaken in Stata (version 17).

167

168 Results

169 A total of 322 studies were found in the databases, published between January 1, 2017, and May 17, 170 2023, of which 300 were excluded after screening titles and abstracts (Figure 2). A further 18 studies 171 were excluded because G6PD activity was not measured by Biosensor (n=12), participants were not 172 selected randomly from the whole population (n=4) or the trial was ongoing (n=2). A total of four 173 studies met the eligibility criteria [29-32] and data were available and shared by investigators. Data 174 on sex were not recorded consistently across G6PD categories for one study leading to its exclusion. 175 Data from eight studies unpublished as of May 17, 2023, were also available, providing a total of 11 176 studies on 10,905 participants [33, 34]. Data from 1,181 participants were excluded due to missing 177 variables and haemoglobin measurements <7 g/dL, resulting in 9,724 participants from 11 studies 178 included in the analysis.

Data were included from 8 countries: Bangladesh, Brazil, Cambodia, Ethiopia, India, Indonesia, Nepal,
and the United States of America. The median age was 30.0 years (interquartile range (IQR) 21.0-43.0),
of whom 4,237 (43.6%) were female and 8,938 (91.9%) were sampled using capillary sampling
methods. Malaria was recorded in 2,282 (23.5%) participants. No consistent data were available on

183 pregnancy, previous malaria episodes, recent surgery, recent blood loss, or recent blood transfusions.

184 There were 14 unique settings (country and study categories), of which 2 (14%) had unclear or possible

185 risk of bias (Table S1 - QUADAS).

186 The distribution of G6PD activities in male participants showed two peaks consistent with presumed 187 G6PD deficient and G6PD normal populations (Figure 3). Visually, the nadir in the overlapping region 188 between these peaks occurred at ~3.5 U/gHb. The universal AMM, derived from 3,959 males without 189 parasitaemia, was 7.7 U/gHb and from this the 30% cutoff was determined to be 2.3 U/gHb and the 190 70% cutoff was determined to be 5.4 U/gHb (Table 2 and Figure 3). The AMM calculated for each setting varied substantially from 6.2 U/gHb in one study from Nepal to 9.9 U/gHb in a study in 191 192 Bangladesh [33, 34]. The setting-specific cutoffs for 30% G6PD activity ranged from 1.9 U/g Hb to 3.0 193 U/g Hb and the corresponding setting-specific 70% cutoffs varied from 4.3 U/gHb to 6.9 U/gHb (Table 194 2).

195 Using the manufacturer's cutoff of 4.0 U/gHb, 7.2% (699) of all participants in this analysis were 196 classified as deficient (72.8% (509) were males), but this decreased to 4.2% (411) when the universal 197 30% cutoff of 2.3 U/gHb was applied (Figure 3), and 3.9% (301) when the setting-specific 30% cutoffs 198 were applied (Table 2 and Figure 4). Using the manufacturer's cutoff of 6.0 U/gHb, 18.3% (1,777) of 199 participants were classified as having intermediate or deficient G6PD activity (<70%) and this 200 decreased to 11.9% (1,156) when the universal cutoff was applied and 10.8% (830) when the setting-201 specific cutoffs were applied. Of the 1,078 patients with intermediate activity (>4.0-6.0 U/gHb) using 202 the manufacturer's cutoffs, 60.1% (648) were male. The distribution of G6PD activities varied 203 substantially between settings (Figure 4 and Tables 1-2).

Two settings sampled more than 10 individuals whose G6PD activity was measured from both capillary and venous samples [33, 34]. After adjusting for age, sex, baseline Hb, and malaria status with clustering by setting, there was no difference in mean G6PD activity between capillary or venous sampling (mean difference: 0.28 U/gHb, 95% CI -1.27, 1.83).

Data were available from 6 settings on 5,064 participants with and without malaria [33, 34]. After adjusting for confounders, there was no difference in mean G6PD activity between participants with or without malaria (-0.64 U/gHb, 95% CI -1.91, 0.64). Similarly, removing parasitaemic participants did not change the percentages of participants classified as having <30% or <70% G6PD activity substantially (Table S2).

There was a non-linear association between age and G6PD activity and age and haemoglobin (Figure S1). In an exploratory analysis, measured G6PD activity decreased sharply with increasing age in children aged 1 to 5 years and plateaued thereafter, after adjusting for sex, baseline haemoglobin and blood sampling method with clustering by setting (Figure 5). This relationship was apparent in

subgroups of male and female individuals. In sensitivity analyses, the age differences remained apparent when restricted to males with a haemoglobin >10 g/dL and males with G6PD activity >4.0 U/g Hb.

220

221 Discussion

222 A reliable and accurate point-of-care diagnostic for G6PD activity is an important tool for the safe 223 prescription of 8-aminoquinoline antimalarial drugs in vivax-endemic countries. Our individual patient 224 data pooled meta-analysis of over 9,700 participants from 11 studies and eight countries 225 demonstrates substantial heterogeneity in the definition of 100% activity between settings. The 226 current manufacturer-recommended cutoffs to define deficient and intermediate G6PD activity are 227 conservative, placing a higher proportion of individuals in the intermediate or deficient category than 228 when applying locally calculated cutoffs. Definitions for 100% activity based on setting-specific AMMs 229 ranged from 6.2 U/gHb to 9.9 U/gHb between settings and this was reflected by significant variation 230 in the respective 30% and 70% cutoffs. A previous study demonstrated that, under ideal laboratory 231 conditions, with trained laboratory staff, the Biosensor performed comparably across different 232 settings [35]. The differences observed in our analysis could therefore be related to differences in user 233 proficiency or inherent differences between sites.

The universal definition of 100% activity in our pooled sample was 7.7 U/gHb according to the Biosensor, and the corresponding cutoff for 30% activity (2.3 U/gHb) that was derived from this AMM appeared to exclude a substantial proportion of presumed deficient males from the G6PD deficient group based on the distribution of G6PD activities in the male population (Figure 3 and Figure 4). In comparison, across all settings most male participants at the lower end of the G6PD activity distributions were included in the deficient group using the manufacturer-recommended cutoff of 4.0 U/gHb (Figure 3 and Figure 4).

241 A cutoff at 30% activity defined based on spectrophotometry measurements captures the majority of 242 male deficient patients [15]. In contrast, the Biosensor manufacturer-recommended cutoff of 4.0 243 U/gHb corresponds to 52% activity as determined by the universal AMM. This difference suggests 244 there is an imperfect correlation between G6PD activity measured by spectrophotometry and G6PD 245 activity measured by Biosensor, such that the correlation is not 1:1. Most qualitative G6PD diagnostics 246 distinguish deficient and normal individuals at the 30% activity level, developed based on results from 247 spectrophotometry, and have effectively guided radical cure in males over several decades [36]. 248 Additional investigation of the relationship between Biosensor and spectrophotometric G6PD activity 249 is warranted including assessment of haemolytic risks at various cutoffs to identify whether

adjustments to the manufacturer-recommended cutoff of 4.0 U/gHb to identify G6PD deficient individuals is needed.

252 The manufacturer recommended cutoff of 6.0 U/gHb corresponds to 78% activity using the universal 253 AMM and thus places a higher proportion of participants in the category of intermediate activity. 254 Treatment with high dose primaguine radical cure (1 mg/kg/day for 7 days) potentially has a greater 255 risk of haemolysis in heterozygous females with intermediate activity [37, 38]. A recent clinical trial in 256 Bangladesh, Ethiopia and Indonesia provided this high dose primaquine radical cure regimen to 257 individuals with \geq 70% activity based on the local AMM. At one site the corresponding cut-off was 5 258 U/gHb, well below the manufacturer recommended 6.0 U/gHb cutoff for intermediate patients, with 259 no treatment-related serious adverse events observed, and no patients developing severe anaemia 260 (haemoglobin <5 g/dL) [39]. This study and previous studies suggest that patients with activities below 261 6.0 U/gHb may tolerate high dose primaquine and the optimal cutoff to determine heterozygous 262 female patients at risk of severe haemolysis requires further investigation [40].

263 Neither the source of blood sampling nor malaria status impacted phenotypic G6PD activity, but G6PD 264 activity did vary with age. Measured G6PD activity decreased from ~11 U/gHb to ~8 U/gHb as age 265 increased from one to five years before plateauing thereafter. A decrease in G6PD activity over the 266 first 6 to 12 months of life had been described previously, however, to our knowledge, this has not 267 been observed in older children [41, 42]. This observation warrants further investigation since it may 268 relate to either a true variation in enzyme activity, other influential parameters such as haemoglobin 269 varying over age, or specific features associated with point of care testing with the Biosensor. If 270 confirmed, this will have important clinical relevance, including the potential for reduced susceptibility 271 to drug-induced haemolysis in young children and hence increased confidence in administering the 272 radical cure in children [43]. If this finding is specific for the Biosensor, it may require an age-based 273 adjustment in results in young children to ensure children are not falsely classified as G6PD normal.

274 Our study has several limitations. The proportion of individuals with G6PD deficiency is known to vary 275 substantially between and within countries [44]. Although data from nearly 10,000 individuals from 276 eight countries were included, the study population is not necessarily representative of all populations 277 in vivax endemic regions. Furthermore, setting-specific cutoffs may have been influenced by 278 differences in participant age as well as sample handling, though G6PD activity remains stable for at 279 least seven days if samples are stored between 4°C to 8°C [45, 46]. Data were not available on 280 pregnancy, recent surgery, recent blood loss, or recent blood transfusion, preventing any adjustment 281 for their effect on G6PD activity [8, 47, 48]. The pooled G6PD activity measurements did not have a 282 paired spectrophotometric reference measurement, preventing assessment of systematic bias in 283 specific settings. Due to the absence of a reference method, it was also not possible to compare the

- 284 performance of universal and manufacturer recommended cutoffs against a gold-standard method,
- instead we had to rely on visual inspection of activity distributions.
- 286 In the absence of clinical data on haemolysis it was not possible to correlate Biosensor G6PD activity
- with haemolytic risks, preventing an understanding of how different cutoffs would perform in a clinical
- 288 population undergoing 8-aminoquinoline therapy.
- 289 In conclusion, there was a substantial difference between the manufacturer-recommended cutoffs for
- 290 G6PD deficient and intermediate individuals and those derived using the current dataset based on
- 291 30% and 70% thresholds with the G6PD Standard definitions being more conservative. Further clinical
- 292 studies are needed to determine the relationship between spectrophotometry and Biosensor G6PD
- 293 activity measurements and the cutoffs that best predict the risk of drug-induced haemolysis.
- 294 295
- 296 Acknowledgements

We thank all participants and staff who were involved in these clinical trials at all the sites. This research has been supported by the Australian Government through the Partnerships for a Healthy Region (PHR) initiative. The views expressed in this publication are the author's alone and are not necessarily the views of the Australian Government.

- 301
- 302

303 Funding

This work was supported by an NHMRC Ideas Grant (2028979), the content of this article does not necessarily reflect the views of the NHMRC. RJC is supported by an Australian National Health and Medical Research Council (NHMRC) Investigator Grants (1194702).

307

308 Data sharing

309 Study data can be obtained by request to the corresponding authors of the included studies.

 Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the gl endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet. 2019. Epub 2019/06/24. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era o Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560-70. doi: 10.1016/j.pt.2020.03.00 PubMed PMID: 32407682; PubMed Central PMCID: PMCPMC729727. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the gl endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet. 2019;394(10195):332-43. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMCPMC6675736. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-245 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenass Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M	
 Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the gl endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modellin, study. Lancet. 2019. Epub 2019/06/24. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era o Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560-70. doi: 10.1016/j.pt.2020.03.00 PubMed PMID: 32407682; PubMed Central PMCID: PMCPMC7297627. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the gl endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modellin, study. Lancet. 2019;394(10195):332-43. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMCPMC6675736. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EP the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenass Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzz	
 study. Lancet. 2019. Epub 2019/06/24. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era o Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560-70. doi: 10.1016/j.pt.2020.03.00 PubMed PMID: 32407682; PubMed Central PMCID: PMCPMC7297627. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the gl endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet. 2019;394(10195):332-43. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMCPMC6675736. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-243 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenass Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blod. 2 	obal 3
 Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era o Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560-70. doi: 10.1016/j.pt.2020.03.00 PubMed PMID: 32407682; PubMed Central PMCID: PMCPMC7297627. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the gl endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modellini study. Lancet. 2019;394(10195):332-43. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMCPMC6675736. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenass Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 2 doi: 10.1182/	
 Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560-70. doi: 10.1016/j.pt.2020.03.00 PubMed PMID: 32407682; PubMed Central PMCID: PMCPMC7297627. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the gl endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet. 2019;394(10195):332-43. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMCPMC6675736. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 2 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blo 	f the
 PubMed PMID: 32407882; PubMed Central PMCD: PMCPMC729627. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the gl endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet. 2019;394(10195):332-43. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMCPMC6675736. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenass Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 2 doi: 10.1182/blood.201900944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood 2005 10.1182/blood.201900944. PubMed PMID: 32702756. 	9.
 Battle KE, Lucas TCD, Nguyen M, Howes KE, Nandi AK, Twonig KA, et al. Mapping the gi endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study. Lancet. 2019;394(10195):332-43. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMCPMC6675736. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-245 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 21 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blo doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. 	
 endemicity and clinical burden of Plasmodium Vivax, 2000-17: a spatial and temporal modelling study. Lancet. 2019;394(10195):332-43. doi: 10.1016/S0140-6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMCPMC6675736. 4. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. 5. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-245 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. 6. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. 7. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. 8. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 21 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. 9. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blo 	obai
 31229233; PubMed Central PMCID: PMCPMC6675736. Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 21 doi: 10.1182/blood.201900944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blo 	5
 Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The ris morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249. PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 24 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blo 	
 morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohor study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 21 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blo 	k of
 study. BMC Med. 2020;18(1):28. doi: 10.1186/s12916-020-1497-0. PubMed PMID: 32075649; PubMed Central PMCID: PMCPMC7031957. Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 20 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blo 	t
 Kondrashin AV, Morozova LF, Stepanova EV, Turbabina NA, Maksimova MS, Morozov EN the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 24 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Bloce 	
 the epidemiology of Plasmodium vivax malaria: past and present with special reference to the former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 24 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Bloc 	J. On
 former USSR. Malaria journal. 2018;17(1):346. Epub 2018/10/06. doi: 10.1186/s12936-018-249 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. 6. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. 7. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. 8. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 24 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. 9. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Block 	
 PubMed PMID: 30286752; PubMed Central PMCID: PMCPMC6172834. Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 24 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Block 	Э5-у.
 Phru CS, Kibria MG, Thriemer K, Chowdhury MU, Jahan N, Aktaruzzaman MM, et al. Ca Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenase Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 20 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Block 	•
 Report: A Case of Primaquine-Induced Hemoglobinuria in Glucose-6-Phosphate Dehydrogenast Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 24 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Block 	se
 Deficient Malaria Patient in Southeastern Bangladesh. Am J Trop Med Hyg. 2019. doi: 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. 7. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. 8. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 24 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. 9. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Block 	3-
 10.4269/ajtmh.19-0643. PubMed PMID: 31701865. Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 20 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Block 	
 Chu CS, Hwang J. Tafenoquine: a toxicity overview. Expert Opin Drug Saf. 2021;20(3):34 Epub 2020/12/12. doi: 10.1080/14740338.2021.1859476. PubMed PMID: 33306921. Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 24 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Block 	
 Luzzatto L, Ally M, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Blood. 2 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Block 	9-62.
 doi: 10.1182/blood.2019000944. PubMed PMID: 32702756. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blo 	020.
339 9. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blo	
	od.
340 2008;111(1):16-24. doi: 10.1182/blood-2007-04-077412. PubMed PMID: 18156501.	
341 10. Alam M, Kibria M, Jahan N, Price R, Ley B. Spectrophotometry assays to determine G6F	D
342 activity from Trinity Biotech and Pointe Scientific G6PD show good correlation. BMC Research N	lotes.
343 2018;11(1):1-4.	
11. Pfeffer D, Ley B, Howes R, Adu P, Alam M, Bansil P, et al. Quantification of glucose-6-	
345 phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analy	sis.
346 PLoS Medicine. 2020;17(5):10030841.	
12. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, et al. G6PD testing	g in
348 support of treatment and elimination of malaria: recommendations for evaluation of G6PD tes	ts.
349 Malar J. 2013;12:391. Epub 2013/11/06. doi: 10.1186/1475-2875-12-391. PubMed PMID: 2418	8096;
350 PubMed Central PMCID: PMC3830439.	
351 13. Gomez-Manzo S, Marcial-Quino J, Vanoye-Carlo A, Serrano-Posada H, Ortega-Cuellar D	,
352 Gonzalez-Valdez A, et al. Glucose-6-Phosphate Dehydrogenase: Update and Analysis of New	
353 Mutations around the World. Int J Mol Sci. 2016;17(12). Epub 20161209. doi:	
354 10.3390/ijms17122069. PubMed PMID: 27941691; PubMed Central PMCID: PMCPMC5187869	
355 14. Nannelli C, Bosman, A., Cunningham, J., Dugue, A.P., Luzzatto, L. Genetics ariants causin	וg
356 G6PD deficiency: biohcemical and clinical data suppoert new WHO classification. British Journa	l of
357 Haematology. 2023;202(5):1024-32. Epub 06 July 2023.	
358 15. Pfeffer DA, Satyagraha AW, Sadhewa A, Alam MS, Bancone G, Boum Y, et al. Genetic va	riants
of glucose-6-phosphate dehydrogenase and their associated enzyme activity: a systematic revieand meta-analysis. Pathogens. 2022;11(9):1045.	5M

medRxiv preprint doi: https://doi.org/10.1101/2024.12.20.24319407; this version posted December 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

Ley B, Kibria M, Khan W, Auburn S, Phru C, Jahan N, et al. Wide range of G6PD activities

found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. PLOS Neglected Tropical

361

362

16.

363 Diseases. 2020;14(9):8697--1. 364 WHO. WHO Guidelines for malaria, 14 March 2023. In: Organization WH, editor. Geneva, 17. 365 Switzerland2023. 366 18. Llanos-Cuentas A, Lacerda MVG, Hien TT, Velez ID, Namaik-Larp C, Chu CS, et al. Tafenoquine 367 versus Primaguine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 2019;380(3):229-368 41. Epub 2019/01/17. doi: 10.1056/NEJMoa1802537. PubMed PMID: 30650326. 369 19. Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. 370 Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 371 2019;380(3):215-28. Epub 2019/01/17. doi: 10.1056/NEJMoa1710775. PubMed PMID: 30650322; 372 PubMed Central PMCID: PMCPMC6657226. 373 20. WHO Global Malaria Programme Malaria Policy Advisory Group. Meeting report of the 374 technical consultation to review the classification of glucose-6-phosphate dehydrogenase (G6PD). 375 Geneva, Switzerland: 2022 WHO/UCN/GMP/MPAG/2022.01. 376 21. Pfeffer DA, Satyagraha AW, Sadhewa A, Alam MS, Bancone G, Boum Y, et al. Genetic Variants 377 of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review 378 and Meta-Analysis. Pathogens. 2022;11(9). doi: 10.3390/pathogens11091045. 379 22. Sadhewa A, Cassidy-Seyoum S, Acharya S, Devine A, Price RN, Mwaura M, et al. A Review of 380 the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria. 381 Pathogens. 2023;12(5):650. PubMed PMID: doi:10.3390/pathogens12050650. 382 Adhikari B, Tripura R, Dysoley L, Peto TJ, Callery JJ, Heng C, et al. Glucose-6-Phosphate 23. 383 Dehydrogenase (G6PD) Measurement Using Biosensors by Community-Based Village Malaria 384 Workers and Hospital Laboratory Staff in Cambodia: A Quantitative Study. Pathogens. 2023;12(3). 385 Epub 2023/03/30. doi: 10.3390/pathogens12030400. PubMed PMID: 36986323; PubMed Central 386 PMCID: PMCPMC10056797. 387 Ley B, Winasti Satyagraha A, Kibria MG, Armstrong J, Bancone G, Bei AK, et al. Repeatability 24. 388 and reproducibility of a handheld quantitative G6PD diagnostic. PLoS Negl Trop Dis. 389 2022;16(2):e0010174. Epub 2022/02/18. doi: 10.1371/journal.pntd.0010174. PubMed PMID: 390 35176015; PubMed Central PMCID: PMCPMC8853557. 391 Martínez JC, Vélez-Marín V, Lopez-Perez M, Patiño-Lugo DF, Florez ID. Diagnostic accuracy of 25. 392 the point-of-care standard G6PD test[™] (SD Biosensor) for glucose-6-phosphate dehydrogenase 393 deficiency: a systematic review and meta-analysis. Malar J. 2024;23(1):327. Epub 20241102. doi: 394 10.1186/s12936-024-05144-1. PubMed PMID: 39488711; PubMed Central PMCID: 395 PMCPMC11531698. 396 26. Adissu W, Brito M, Garbin E, Macedo M, Monteiro W, Mukherjee SK, et al. Clinical 397 performance validation of the STANDARD G6PD test: A multi-country pooled analysis. PLoS Negl Trop 398 Dis. 2023;17(10):e0011652. Epub 2023/10/12. doi: 10.1371/journal.pntd.0011652. PubMed PMID: 399 37824592; PubMed Central PMCID: PMCPMC10597494. 400 27. Adhikari B, Tripura R, Dysoley L, Peto TJ, Callery JJ, Heng C, et al. Glucose-6-phosphate 401 dehydrogenase (G6PD) measurement using biosensors by community-based village malaria workers 402 and hospital laboratory staff in Cambodia: a quantitative study. Pathogens. 2023;12(3):400. 403 Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a 28. 404 revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine. 405 2011;155(8):529-36. Epub 2011/10/19. doi: 10.1059/0003-4819-155-8-201110180-00009. PubMed 406 PMID: 22007046. 407 29. Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino Freitas S, Macedo M, et al. 408 Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in 409 Brazil. PLoS Negl Trop Dis. 2021;15(8):e0009649. doi: 10.1371/journal.pntd.0009649. PubMed PMID: 410 34383774; PubMed Central PMCID: PMCPMC8384181.

perpetuity. It is made available under a CC-BY 4.0 International license .

of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick

Pal S, Myburgh J, Bansil P, Hann A, Robertson L, Gerth-Guyette E, et al. Reference and point-

413 equivalence and precision. PLoS One. 2021;16(9):e0257560. doi: 10.1371/journal.pone.0257560. 414 PubMed PMID: 34543346; PubMed Central PMCID: PMCPMC8452025. 415 Brito-Sousa JD, Murta F, Vitor-Silva S, Sampaio V, Mendes M, Souza B, et al. Quantitative 31. 416 G6PD Deficiency Screening in Routine Malaria Diagnostic Units in the Brazilian Amazon (SAFEPRIM): 417 An Operational Mixed-Methods Study. Pathogens. 2022;11(11):1328. PubMed PMID: 418 doi:10.3390/pathogens11111328. 419 32. Adhikari B, Tripura R, Dysoley L, Callery JJ, Peto TJ, Heng C, et al. Glucose 6 Phosphate 420 Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method 421 study in Cambodia. Malaria Journal. 2022;21(1):282. 422 33. Adissu W, Brito M, Garbin E, Macedo M, Monteiro W, Mukherjee SK, et al. Clinical 423 performance validation of the STANDARD G6PD test: A multi-country pooled analysis. PLoS 424 Neglected Tropical Diseases. 2023;17(10):e0011652. 425 34. Sadhewa A, Chaudhary A, Panggalo LV, Rumaseb A, Adhikari N, Adhikari S, et al. Field 426 assessment of the operating procedures of a semi-quantitative G6PD Biosensor to improve 427 repeatability of routine testing. Plos one. 2024;19(1):e0296708. 428 35. Ley B, Satyagraha AW, Kibria MG, Armstrong J, Bizij G, Bancone G, et al. The standard G6PD 429 test (SD biosensor) shows good repeatability and reproducibility in a multi-laboratory comparison. 430 American Journal of Tropical Medicine and Hygiene. 2021;105(5S). 431 Ley B, Luter N, Espino F, Devine A, Kalnoky M, Lubell Y, et al. The challenges of introducing 36. 432 routine G6PD testing into radical cure: a workshop report. Malaria journal. 2015;14(1):377-. 433 37. Rajasekhar M, Simpson JA, Ley B, Edler P, Chu CS, Abreha T, et al. Primaquine dose and the 434 risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and 435 individual patient data meta-analysis. Lancet Infect Dis. 2024;24(2):184-95. Epub 20230922. doi: 436 10.1016/s1473-3099(23)00431-0. PubMed PMID: 37748497; PubMed Central PMCID: 437 PMCPMC7615565. 438 38. Chu CS, Bancone G, Nosten F, White NJ, Luzzatto L. Primaquine-induced haemolysis in 439 females heterozygous for G6PD deficiency. Malar J. 2018;17(1):101. doi: 10.1186/s12936-018-2248-y. 440 PubMed PMID: 29499733. 441 39. Thriemer K, Degaga TS, Christian M, Alam MS, Rajasekhar M, Ley B, et al. Primaguine radical 442 cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and 443 Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial. The 444 Lancet. 2023;402(10417):2101-10. 445 40. Taylor W, Thriemer K, Seidlein Lv, Yuentrakul P, Assawariyathipat T, ... Short-course 446 primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-447 controlled non-inferiority trial. The Lancet. 2019;394(10202):929-38. 448 41. Yang W-C, Tai S, Hsu C-L, Fu C-M, Chou A-K, Shao P-L, et al. Reference levels for glucose-6-449 phosphate dehydrogenase enzyme activity in infants 7–90 days old in Taiwan. Journal of the 450 Formosan Medical Association. 2019. doi: https://doi.org/10.1016/j.jfma.2019.03.010. 451 42. Isaac I, Mainasara A, Erhabor O, Omojuyigbe S, Dallatu M, Bilbis L, et al. Glucose-6-452 phosphate dehydrogenase deficiency among children attending the Emergency Paediatric Unit of 453 Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria. Int J Gen Med. 2013;6:557-62. Epub 454 20130709. doi: 10.2147/ijgm.S43757. PubMed PMID: 23874116; PubMed Central PMCID: 455 PMCPMC3711754. 456 43. Pukrittayakamee S, Jittamala P, Watson JA, Hanboonkunupakarn B, Leungsinsiri P, 457 Poovorawan K, et al. Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive 458 pharmacometric assessment of ascending dose regimens in healthy volunteers. Elife. 2024;12. Epub 459 2024/02/06. doi: 10.7554/eLife.87318. PubMed PMID: 38319064; PubMed Central PMCID:

460 PMCPMC10945527.

411

412

30.

medRxiv preprint doi: https://doi.org/10.1101/2024.12.20.24319407; this version posted December 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

461 44. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency 462 prevalence and estimates of affected populations in malaria endemic countries: a geostatistical 463 model-based map. PLoS medicine. 2012;9(11):e1001339.

464 45. Alam M, Kibria M, Jahan N, Thriemer K, Hossain M, Douglas N, et al. Field evaluation of 465 quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PloS 466 one. 2018;13(11):206331--1.

467 Kahn M, Ward WH, LaRue N, Kalnoky M, Pal S, Domingo GJ. Maintaining Specimen Integrity 46. 468 for G6PD Screening by Cytofluorometric Assays. J Histochem Cytochem. 2015;63(6):454-8. doi:

469 10.1369/0022155415580594. PubMed PMID: 25786434; PubMed Central PMCID: PMCPMC4442822.

470 Ley B, Bancone G, Seidlein LV, Thriemer K, Richards J, Domingo G, et al. Methods for the field 47. 471 evaluation of quantitative G6PD diagnostics: a review. Malaria journal. 2017;16(1):1-9.

472 Ley B, Alam MS, Kibria MG, Marfurt J, Phru CS, Ami JQ, et al. Glucose-6-phosphate 48.

- 473 dehydrogenase activity in individuals with and without malaria: Analysis of clinical trial, cross-
- 474 sectional and case-control data from Bangladesh. PLOS Medicine. 2021;18(4):e1003576. doi:
- 475 10.1371/journal.pmed.1003576.

477 Figure 2. Flow diagram of patient inclusion





480 Table 1. Demographics and baseline measures by setting

Country	Study	Participants	Age	Sex		Malaria	present	Blood sam	Haemoglobin	
Country	Study	Participants		Male	Female	No or unknown	Yes	Venous	Capillary	(g/dL)
Overall		9,724	30.0 (21.0-43.0)	5,487 (56.4%)	4,237 (43.6%)	7,442 (76.5%)	2,282 (23.5%)	786 (8.1%)	8,938 (91.9%)	13.5 (12.0-15.0)
Bangladesh	ACROSS 2019 [33]	468	35.0 (15.0-45.0)	269 (57.5%)	199 (42.5%)	468 (100.0%)	0 (0.0%)	468 (100.0%)	0 (0.0%)	14.4 (13.0-15.8)
Brazil	Brito-Sousa 2022 [31]	1,097	23.0 (12.0-39.0)	674 (61.4%)	423 (38.6%)	0 (0.0%)	1,097 (100.0%)	0 (0.0%)	1,097 (100.0%)	12.9 (11.3-14.4)
	PATH 2019 [33]	1,730	37.0 (27.0-47.0)	785 (45.4%)	945 (54.6%)	1,480 (85.5%)	250 (14.5%)	8 (0.5%)	1,722 (99.5%)	13.2 (12.0-14.5)
Cambodia	Adhikari 2022 [32]	1,327	31.0 (23.0-42.0)	993 (74.8%)	334 (25.2%)	1,259 (94.9%)	68 (5.1%)	0 (0.0%)	1,327 (100.0%)	14.0 (12.4-15.7)
camboana	EFFORT 2023	282	26.0 (21.0-35.0)	251 (89.0%)	31 (11.0%)	5 (1.8%)	277 (98.2%)	0 (0.0%)	282 (100.0%)	14.6 (13.3-15.7)
Fthionia	EFFORT 2023	373	23.0 (19.0-30.0)	211 (56.6%)	162 (43.4%)	0 (0.0%)	373 (100.0%)	0 (0.0%)	373 (100.0%)	14.0 (12.5-15.5)
Ethiopia	PATH 2019 [33]	1,013	24.0 (21.0-31.0)	538 (53.1%)	475 (46.9%)	1,013 (100.0%)	0 (0.0%)	0 (0.0%)	1,013 (100.0%)	14.6 (13.2-16.2)
	ACROSS 2018	752	31.0 (11.0-47.5)	310 (41.2%)	442 (58.8%)	743 (98.8%)	9 (1.2%)	0 (0.0%)	752 (100.0%)	13.5 (12.4-14.9)
Indonesia	EFFORT 2023	195	28.0 (19.0-40.0)	134 (68.7%)	61 (31.3%)	6 (3.1%)	189 (96.9%)	0 (0.0%)	195 (100.0%)	14.1 (12.6-15.4)
	Sadhewa 2024 [34]	59	35.0 (29.0-42.0)	14 (23.7%)	45 (76.3%)	59 (100.0%)	0 (0.0%)	0 (0.0%)	59 (100.0%)	16.0 (14.6-17.1)
la dia	ACROSS 2020 [33]	778	33.0 (20.0-47.0)	359 (46.1%)	419 (53.9%)	759 (97.6%)	19 (2.4%)	250 (32.1%)	528 (67.9%)	13.2 (11.7-14.8)
india	PATH 2020 [33]	909	35.0 (23.0-50.0)	585 (64.4%)	324 (35.6%)	909 (100.0%)	0 (0.0%)	0 (0.0%)	909 (100.0%)	12.3 (10.8-13.8)
Nepal	Sadhewa 2024 [34]	120	32.0 (21.0-50.0)	51 (42.5%)	69 (57.5%)	120 (100.0%)	0 (0.0%)	60 (50.0%)	60 (50.0%)	14.2 (13.1-16.2)
USA	Pal 2021 [30]	621	34.0 (26.0-48.0)	313 (50.4%)	308 (49.6%)	621 (100.0%)	0 (0.0%)	0 (0.0%)	621 (100.0%)	12.4 (11.4-13.7)

481 IQR – interquartile range





485 Blue bars correspond to males. Orange bars correspond to females. Red dotted lines correspond to 30% and 70% activity of the universal AMM. Black dotted 486 lines correspond to the manufacturer recommended cutoff of 4.0 U/gHb and 6.0 U/gHb.

Country	Study	Dorticinonto	100% AMM,	30% AMM,	Percentage (n) identified as <30% cutoff by:			70% AMM,	Percentage identified as <70% cutoff by:		
Country	Study	Participants	U/gHb	U/gHb	Manufacturer (n)	Universal (n)	Setting (n)	U/gHb	Manufacturer (n)	Universal (n)	Setting (n)
Overall		9,724	7.7	2.3	7.2% (699)	4.2% (411)	3.9% (301)	5.4	18.3% (1,777)	11.9% (1,156)	10.8% (830)
Bangladesh	ACROSS 2019 [33]	468	9.9	3.0	7.7% (36)	6.0% (28)	7.1% (33)	6.9	9.6% (45)	8.8% (41)	11.5% (54)
Brazil	Brito-Sousa 2022 [31]	1,097	-	-	5.9% (65)	2.6% (29)	-	-	19.1% (209)	11.9% (130)	-
Brazil [F Cambodia [Ethiopia	PATH 2019 [33]	1,730	7.5	2.3	5.5% (95)	3.3% (57)	3.1% (53)	5.3	15.5% (268)	9.9% (171)	9.3% (161)
Cambodia	Adhikari 2022 [32]	1,327	6.4	1.9	21.5% (285)	13.3% (176)	9.9% (132)	4.5	44.1% (585)	33.8% (449)	24.8% (329)
	EFFORT 2023	282	-	-	11.3% (32)	10.3% (29)	-	-	33.7% (95)	16.7% (47)	-
Ethiania	EFFORT 2023	373	-	-	2.1% (8)	0.3% (1)	-	-	25.2% (94)	5.1% (19)	-
Cambodia Ethiopia Indonesia	PATH 2019 [33]	1,013	7.5	2.3	1.9% (19)	0.8% (8)	0.8% (8)	5.3	7.9% (80)	3.7% (37)	3.7% (37)
	ACROSS 2018	752	8.6	2.6	2.0% (15)	0.9% (7)	0.9% (7)	6.0	3.9% (29)	2.3% (17)	3.9% (29)
Indonesia	EFFORT 2023	195	-	-	4.6% (9)	2.1% (4)	-	-	30.8% (60)	9.2% (18)	-
	Sadhewa 2024 [34]	59	-	-	1.7% (1)	1.7% (1)	-	-	28.8% (17)	8.5% (5)	-
India	ACROSS 2020 [33]	778	8.3	2.5	2.3% (18)	1.3% (10)	1.3% (10)	5.8	7.1% (55)	4.9% (38)	6.6% (51)
Inula	PATH 2020 [33]	909	8.3	2.5	5.1% (46)	2.9% (26)	2.9% (26)	5.8	8.6% (78)	6.7% (61)	7.9% (72)
Nepal	Sadhewa 2024 [34]	120	6.2	1.9	7.5% (9)	1.7% (2)	0.8% (1)	4.3	34.2% (41)	25.8% (31)	10.0% (12)
USA	Pal 2021 [30]	621	7.3	2.2	9.8% (61)	5.3% (33)	5.0% (31)	5.1	19.5% (121)	14.8% (92)	13.7% (85)

488 AMM – adjusted male median; An AMM was not calculated for Sadhewa et al in Indonesia [34] due to too few male participants. An AMM was not

489 calculated for EFFORT in Cambodia, Ethiopia and Indonesia, and Brito-Sousa et al in Brazil [31] as included participants were predominantly parasitaemic.

491 Figure 4. Density of G6PD activity in A) males and B) females by setting

A)





500 501

502 Red dotted lines correspond to 30% and 70% activity of the universal AMM. Black dotted lines correspond to the manufacturer recommended

503 cutoff of 4.0 U/gHb and 6.0 U/gHb. Green dotted lines correspond to 30% and 70% activity of the setting-specific AMM. Setting-specific AMMs 504 were not available for EFFORT in Cambodia, Ethiopia and Indonesia, Sadhewa et al in Indonesia [34] and Brito-Sousa et al in Brazil [31].





506

507 Based on a generalised estimating equation model with fractional polynomial terms for age, adjusted for

sex, haemoglobin and blood sampling method with clustering by setting after exclusion of participants with
 haemoglobin <7 g/dL or >20 g/dL.

Checklist S1. PRISMA-IPD Checklist of items to include when reporting a systematic review and meta-analysis of individual participant data (IPD)

PRISMA-IPD	Item	Checklist item	Reported						
Section/topic	NO		on page						
Title									
Title	1	Identify the report as a systematic review and meta-analysis of individual participant data.	1						
Abstract									
Structured	2	Provide a structured summary including as applicable:							
Summary		Background : state research question and main objectives, with information on participants, interventions, comparators and outcomes.							
		Methods : report eligibility criteria; data sources including dates of last bibliographic search or elicitation, noting that IPD were sought; methods of assessing risk of bias.	2						
		Results : provide number and type of studies and participants identified and number (%) obtained; summary effect estimates for main outcomes (benefits and harms) with confidence intervals and measures of statistical heterogeneity. Describe the direction							
		and size of summary effects in terms meaningful to those who would put findings into practice.							
		Discussion: state main strengths and limitations of the evidence, general interpretation of the results and any important implications.							
		Other: report primary funding source, registration number and registry name for the systematic review and IPD meta-analysis.							
Introduction	•								
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4						
Objectives	4	Provide an explicit statement of the questions being addressed with reference, as applicable, to participants, interventions, comparisons, outcomes and study design (PICOS). Include any hypotheses that relate to particular types of participant-level subgroups.	4						
Methods									
Protocol and registration	5	Indicate if a protocol exists and where it can be accessed. If available, provide registration information including registration number and registry name. Provide publication details, if applicable.	5						
Eligibility criteria	6	Specify inclusion and exclusion criteria including those relating to participants, interventions, comparisons, outcomes, study design and characteristics (e.g. years when conducted, required minimum follow-up). Note whether these were applied at the study or individual level i.e. whether eligible participants were included (and ineligible participants excluded) from a study that included a wider population than specified by the review inclusion criteria. The rationale for criteria should be stated.	5						
Identifying studies -	7	Describe all methods of identifying published and unpublished studies including, as applicable: which bibliographic databases were searched with dates of coverage; details of any hand searching including of conference proceedings; use of study registers	5						

information sources		and agency or company databases; contact with the original research team and experts in the field; open adverts and surveys. Give the date of last search or elicitation.	
Identifying studies - search	8	Present the full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection processes	9	State the process for determining which studies were eligible for inclusion.	5
Data collection processes	10	Describe how IPD were requested, collected and managed, including any processes for querying and confirming data with investigators. If IPD were not sought from any eligible study, the reason for this should be stated (for each such study). If applicable, describe how any studies for which IPD were not available were dealt with. This should include whether, how and what aggregate data were sought or extracted from study reports and publications (such as extracting data independently in	5
		duplicate) and any processes for obtaining and confirming these data with investigators.	
Data items	11	Describe how the information and variables to be collected were chosen. List and define all study level and participant level data that were sought, including baseline and follow-up information. If applicable, describe methods of standardising or translating variables within the IPD datasets to ensure common scales or measurements across studies.	5
IPD integrity	A1	Describe what aspects of IPD were subject to data checking (such as sequence generation, data consistency and completeness, baseline imbalance) and how this was done.	5
Risk of bias assessment in individual studies.	12	Describe methods used to assess risk of bias in the individual studies and whether this was applied separately for each outcome. If applicable, describe how findings of IPD checking were used to inform the assessment. Report if and how risk of bias assessment was used in any data synthesis.	6
Specification of outcomes and effect measures	13	State all treatment comparisons of interests. State all outcomes addressed and define them in detail. State whether they were pre-specified for the review and, if applicable, whether they were primary/main or secondary/additional outcomes. Give the principal measures of effect (such as risk ratio, hazard ratio, difference in means) used for each outcome.	6
Synthesis methods	14	 Describe the meta-analysis methods used to synthesise IPD. Specify any statistical methods and models used. Issues should include (but are not restricted to): Use of a one-stage or two-stage approach. How effect estimates were generated separately within each study and combined across studies (where applicable). Specification of one-stage models (where applicable) including how clustering of patients within studies was accounted for. Use of fixed or random effects models and any other model assumptions, such as proportional hazards. How (summary) survival curves were generated (where applicable). Methods for quantifying statistical heterogeneity (such as l² and t²). How studies providing IPD and not providing IPD were analysed together (where applicable). 	6

		How missing data within the IPD were dealt with (where applicable).	
Exploration of variation in effects	A2	If applicable, describe any methods used to explore variation in effects by study or participant level characteristics (such as estimation of interactions between effect and covariates). State all participant-level characteristics that were analysed as potential effect modifiers, and whether these were pre-specified.	6
Risk of bias across studies	15	Specify any assessment of risk of bias relating to the accumulated body of evidence, including any pertaining to not obtaining IPD for particular studies, outcomes or other variables.	N/A
Additional analyses	16	Describe methods of any additional analyses, including sensitivity analyses. State which of these were pre-specified.	6
Results	•		
Study selection and IPD obtained	17	Give numbers of studies screened, assessed for eligibility, and included in the systematic review with reasons for exclusions at each stage. Indicate the number of studies and participants for which IPD were sought and for which IPD were obtained. For those studies where IPD were not available, give the numbers of studies and participants for which aggregate data were available. Report reasons for non-availability of IPD. Include a flow diagram.	6, Figure 1
Study characteristics	18	For each study, present information on key study and participant characteristics (such as description of interventions, numbers of participants, demographic data, unavailability of outcomes, funding source, and if applicable duration of follow-up). Provide (main) citations for each study. Where applicable, also report similar study characteristics for any studies not providing IPD.	Table 1
IPD integrity	A3	Report any important issues identified in checking IPD or state that there were none.	Nil
Risk of bias within studies	19	Present data on risk of bias assessments. If applicable, describe whether data checking led to the up-weighting or down- weighting of these assessments. Consider how any potential bias impacts on the robustness of meta-analysis conclusions.	Table S1
Results of individual studies	20	For each comparison and for each main outcome (benefit or harm), for each individual study report the number of eligible participants for which data were obtained and show simple summary data for each intervention group (including, where applicable, the number of events), effect estimates and confidence intervals. These may be tabulated or included on a forest plot.	7
Results of syntheses	21	Present summary effects for each meta-analysis undertaken, including confidence intervals and measures of statistical heterogeneity. State whether the analysis was pre-specified, and report the numbers of studies and participants and, where applicable, the number of events on which it is based.	7
		When exploring variation in effects due to patient or study characteristics, present summary interaction estimates for each characteristic examined, including confidence intervals and measures of statistical heterogeneity. State whether the analysis was pre-specified. State whether any interaction is consistent across trials.	
		Provide a description of the direction and size of effect in terms meaningful to those who would put findings into practice.	

Risk of bias across studies	22	Present results of any assessment of risk of bias relating to the accumulated body of evidence, including any pertaining to the availability and representativeness of available studies, outcomes or other variables.	N/A
Additional analyses	23	Give results of any additional analyses (e.g. sensitivity analyses). If applicable, this should also include any analyses that incorporate aggregate data for studies that do not have IPD. If applicable, summarise the main meta-analysis results following the inclusion or exclusion of studies for which IPD were not available.	7-8
Discussion			
Summary of evidence	24	Summarise the main findings, including the strength of evidence for each main outcome.	8-10
Strengths and limitations	25	Discuss any important strengths and limitations of the evidence including the benefits of access to IPD and any limitations arising from IPD that were not available.	8-10
Conclusions	26	Provide a general interpretation of the findings in the context of other evidence.	8-10
Implications	A4	Consider relevance to key groups (such as policy makers, service providers and service users). Consider implications for future research.	9-10
Funding			
Funding	27	Describe sources of funding and other support (such as supply of IPD), and the role in the systematic review of those providing such support.	10

© Reproduced with permission of the PRISMA IPD Group, which encourages sharing and reuse for non-commercial purposes

Table S1. QUADAS analysis

Country			Percentage (n)	identified as <30%	cutoff by:	Percentage (n) identified as <70% cutoff by:			
	Study	Participants	Manufacturer (n)	Universal (n)	Setting (n)	Manufacturer (n)	Universal (n)	Setting (n)	
Overall		N=7,442	7.5% (557)	4.4% (329)	3.8% (281)	16.6% (1,232)	11.9% (888)	10.6% (782)	
Bangladesh	ACROSS 2019 [33]	N=468	7.7% (36)	6.0% (28)	7.1% (33)	9.6% (45)	8.8% (41)	11.5% (54)	
Brazil	PATH 2019 [33]	N=1,480	5.3% (79)	3.1% (46)	2.8% (42)	13.9% (206)	9.2% (136)	8.6% (128)	
Cambodia	Adhikari 2022 [32]	N=1,259	21.6% (272)	13.3% (167)	9.8% (124)	44.2% (556)	34.0% (428)	25.0% (315)	
	EFFORT 2023	N=5	40.0% (2)	40.0% (2)	-	40.0% (2)	40.0% (2)	-	
Ethiopia	PATH 2019 [33]	N=1,013	1.9% (19)	0.8% (8)	0.8% (8)	7.9% (80)	3.7% (37)	3.7% (37)	
	ACROSS 2018	N=743	2.0% (15)	0.9% (7)	0.9% (7)	3.9% (29)	2.3% (17)	3.9% (29)	
Indonesia	EFFORT 2023	N=6	0.0% (0)	0.0% (0)	-	50.0% (3)	16.7% (1)	-	
indonesia	Sadhewa 2024 [34]	N=59	1.7% (1)	1.7% (1)	-	28.8% (17)	8.5% (5)	-	
India	ACROSS 2020 [33]	N=759	2.2% (17)	1.2% (9)	1.2% (9)	7.1% (54)	4.9% (37)	6.6% (50)	
	PATH 2020 [33]	N=909	5.1% (46)	2.9% (26)	2.9% (26)	8.6% (78)	6.7% (61)	7.9% (72)	
Nepal	Sadhewa 2024 [34]	N=120	7.5% (9)	1.7% (2)	0.8% (1)	34.2% (41)	25.8% (31)	10.0% (12)	
USA	Pal 2021 [30]	N=621	9.8% (61)	5.3% (33)	5.0% (31)	19.5% (121)	14.8% (92)	13.7% (85)	

A setting specific cutoff was not available for EFFORT in Cambodia and Indonesia and Sadhewa et al in Indonesia [34] due to too few male patients to

estimate an adjusted male median.

7 Figure S1. Scatter plot of A) G6PD activity (U/gHb) versus age and B) haemoglobin (g/dL) versus age 8



11 12

A lowess curve using Cleveland's tricube weighting function with a bandwidth of 0.8 is fitted to both figures.

13 Red line = smoothed trend